ClinicalTrials.gg
CompletedNCT04147338Updated Feb 3, 2025

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

A Phase 1 interventional study of Guselkumab in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the serum concentration of guselkumab after administration using three different devices in healthy participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a weight in the range of 50.0 kilogram (kg) to 90.0 kg, inclusive
  • Be healthy on the basis of physical examination, medical history, vital signs, and 12 lead (ECG) performed at screening and Day -1. Any abnormalities must be considered not and this determination must be recorded in the participant's source documents and initialed by the investigator
  • A female participant must have a negative pregnancy test result at screening and baseline (Day -1) and while enrolled in this study
  • (birth control) use by men should be consistent with local regulations (if any) regarding the acceptable methods of contraception for those participating in clinical studies
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 12 weeks after study intervention

Exclusion criteria

Exclusion Criteria:

  • History of any medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal (GI) disease, neurologic or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
  • History of before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence
  • Has a current chronic infection, prior history of recurrent infection, or an active infection
  • Has previously received guselkumab
  • Has a positive urine drug and alcohol screen during screening or at admission (Day -1)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Reference Device: Guselkumab

    Participants will receive subcutaneous (SC) injections of guselkumab in reference device.

    Drug: Guselkumab

  • Experimental
    Test Device 1: Guselkumab

    Participants will receive SC injections of guselkumab in test device 1.

    Drug: Guselkumab

  • Experimental
    Test Device 2: Guselkumab

    Participants will receive SC injections of guselkumab in test device 2.

    Drug: Guselkumab

Interventions

  • Guselkumab will be administered subcutaneously.

    Also known as: CNTO 1959

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Cmax is the maximum observed serum concentration.

    Time frame: Up to Day 85

  2. Area Under the Serum Concentration-Time Curve from Time Zero to Time Infinity (AUC [0-infinity])

    AUC (0-infinity) is the area under the serum concentration-time curve from time zero to infinity time, calculated as the sum of AUC (0-last) and C(last)/lambda(z); wherein AUC (0-last) is area under the serum concentration-time curve from time zero to last measurable concentration, C(last) is the last observed measurable concentration, and lambda(z) is apparent terminal elimination rate constant.

    Time frame: Up to Day 85

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are AEs which will occur up to 113 days that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Up to 113 days

  2. Number of Participants with Clinically Significant Vital Signs Abnormalities

    Number of participants with clinically significant abnormalities in the vital signs including temperature (oral), pulse rate, respiratory rate, and blood pressure will be reported.

    Time frame: Up to 113 days

  3. Number of Participants with Clinically Significant Physical Examination Abnormalities

    Number of participants with clinically significant abnormalities in the physical examination (includes basic assessment of general appearance, respiratory and cardiovascular systems and the assessment of the skin at the administration area) will be reported.

    Time frame: Up to 113 days

  4. Number of Participants with Clinically Significant Laboratory Abnormalities

    Number of participants with clinically significant abnormalities in laboratory assessments like serum chemistry, hematology, and urinalysis will be reported.

    Time frame: Up to 113 days

  5. Number of Participants with Anti-Guselkumab Antibodies

    Number of participants with anti-drug antibodies to guselkumab will be reported.

    Time frame: Up to Day 85

07

Study locations

2 sites
  • Celerion
    Tempe, Arizona 85283, United States
  • CRS Clinical Research Services
    Mannheim, 68167, Germany
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Sep 2021, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2019
First posted
Nov 1, 2019
StartActual
Oct 30, 2019
Primary completionActual
Sep 13, 2021
CompletionActual
Dec 7, 2021
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04147338
Responsible party
Sponsor
First posted
Nov 1, 2019
Start date
Oct 30, 2019
Primary completion
Sep 13, 2021
Completion
Dec 7, 2021
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion